Biosimilars Market Forecasts to 2030 - Global Analysis By Drug Class (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Other Drug Classes), Manufacturing Type (In-house Manufacturing and Contract Manufacturing), Technology (Mass Spectroscopy, Chromatography, Monoclonal Antibody Technology and Other Technologies), Application, End User and By Geography
Estimated Year Value (2023)
US $23.9 BN
Projected Year Value (2030)
US $100.2 BN
CAGR (2023 - 2030)
North America, Europe, Asia Pacific, South America, and Middle East & Africa
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa
Highest Growing Market
According to Stratistics MRC, the Global Biosimilars Market is accounted for $23.9 billion in 2023 and is expected to reach $100.2 billion by 2030 growing at a CAGR of 22.7% during the forecast period. Biosimilars, also known as follow-on biologics, are almost exact replicas of the original drugs but are created by a different company. A variety of acute and chronic illnesses and disorders are treated with biosimilars. The human brain's electrical activity is captured using biosimilars.
According to the International Agency for Research on Cancer 2020, the estimated number of new leukemia cases in 2020 was 474,519 globally.
Strong product pipeline
Pharmaceutical companies with robust pipelines of biosimilar products are well-positioned to meet the increasing demand for cost-effective alternatives to biologic drugs. A diverse and expansive pipeline allows for a broader range of therapeutic options, covering various therapeutic areas and medical conditions. As more biologic drugs approach patent expiration, a well-developed product pipeline can lead to a steady stream of new biosimilar offerings, enhancing competition and availability in the market.
High developmental costs
Developing a biosimilar is a complex and resource-intensive process that involves extensive research, clinical trials, and regulatory approvals. Companies must demonstrate the biosimilar's comparability to the reference biologic through extensive testing, which requires substantial financial investment. Additionally, navigating the regulatory landscape for biosimilars, which often involves more stringent requirements compared to generic drugs, can further escalate development costs. These high costs deter some pharmaceutical companies from entering the biosimilars market, leading to limited competition and potentially delaying the availability of more affordable biosimilar alternatives for patients.
Increasing demand for biosimilars
Biosimilars are cost-effective alternatives to expensive biologic drugs, offering similar therapeutic effects and quality. With rising healthcare costs and the need for affordable treatment options, biosimilars have gained traction among healthcare providers and patients. Governments and healthcare systems worldwide are encouraging the use of biosimilars to enhance accessibility to life-saving medications and reduce healthcare expenditure. As more biologic drugs approach patent expiration, the biosimilars market is expected to expand rapidly, providing patients with greater access to critical treatments and creating opportunities for pharmaceutical companies to compete in this growing and dynamic sector.
Complexities in manufacturing
Biosimilars are complex biologic compounds made in living cells as opposed to conventional small-molecule medications, making the production procedure for them complex and delicate. Cell lines, fermentation, purification, and post-translational changes are just a few of the many variables that need to be carefully controlled in order to guarantee consistency in quality, effectiveness, and safety. Any manufacturing deviation or inconsistency might affect the final product's resemblance to the reference biologic and potentially jeopardize patient safety. The strict regulatory restrictions and expensive research costs related to biosimilars provide additional difficulties, deterring some businesses from joining the market and limiting the supply of patient-friendly biosimilar substitutes.
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the biosimilars market, owing to the implementation of lockdowns in many countries. The COVID-19 pandemic made it impossible for the pharmaceutical sector to concentrate on R&D efforts, particularly the creation of biosimilars. During the epidemic, the whole healthcare sector has concentrated on developing life-saving products. Additionally, pandemic conditions cause delays in product approvals and releases, which further limit the growth of the biosimilars industry.
The recombinant non-glycosylated proteins segment is expected to be the largest during the forecast period
The recombinant non-glycosylated proteins segment is expected to have lucrative growth in the biosimilars market as they represent a crucial class of biologic drugs used to treat various diseases, including cancer, autoimmune disorders, and inflammatory conditions. Biosimilar development for non-glycosylated proteins presents a promising opportunity to offer cost-effective alternatives to expensive reference biologics. As patents for non-glycosylated biologics expire, biosimilar manufacturers can capitalize on this opportunity to provide more affordable treatment options for patients. However, the complexity of manufacturing and demonstrating comparability to the reference products pose challenges in the development and approval processes.
The oncology segment is expected to have the highest CAGR during the forecast period
The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period. With the rising incidence of cancer worldwide, biologic drugs have become essential in the oncology field, but their high costs pose challenges for many patients. Biosimilars offer a promising solution by providing more affordable alternatives to expensive biologics used in cancer therapies. As patents for various oncology biologics expire, biosimilar developers have focused on developing comparable versions, expanding the options available to healthcare providers and patients.
Region with largest share:
During the forecast period, it is expected that the North American Biosimilars market will continue to hold a majority of the market share. Due to its advanced healthcare infrastructure and growing focus on cost-effective treatment options. With several biologic drugs losing patent exclusivity, the region has seen an increase in biosimilars approvals and market entry. Regulatory frameworks, such as the Biologics Price Competition and Innovation Act (BPCIA) in the United States, have paved the way for biosimilars development and commercialization. Moreover, collaborations between pharmaceutical companies and healthcare providers have further facilitated biosimilars adoption.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period. The increasing prevalence of chronic diseases, rising healthcare costs, and the expiration of biologic drug patents has fuelled the demand for cost-effective treatment options. Governments in countries like India, South Korea, and China are actively promoting the adoption of biosimilars to enhance healthcare accessibility and affordability. Additionally, a supportive regulatory environment and streamlined approval processes have encouraged both domestic and international pharmaceutical companies to invest in biosimilar development.
Key players in the market
Some of the key players in Biosimilars market include Coherus Biosciences Inc., Boehringer Ingelheim International GMBH, Eli Lilly and Company, Fresenius Kabi Ag, Samsung Bioepis Co. Ltd, Amgen Inc., LG Life Sciences (LG Chem), Celltrion Healthcare, Biocad, Dr. Reddy’s Laboratories LTD., Viatris Inc., Intas Pharmaceutical Ltd, Biocon Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Stada Arzneimittel AG and Novartis AG.
In May 2023, Boehringer Ingelheim received U.S. FDA clearance for Cyltezo Pen, a novel autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-approved interchangeable biosimilar to Humira.
In January 2023, Amgen Inc. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab) in United States.
In October 2022, Biocon and Yoshindo Inc., entered into an agreement for commercializing Biocon’s pipeline products ustekinumab and bDenosumab in Japan.
Drug Classes Covered:
• Recombinant Non-Glycosylated Proteins
• Recombinant Glycosylated Proteins
• Recombinant Peptides
• Other Drug Classes
Manufacturing Types Covered:
• In-house Manufacturing
• Contract Manufacturing
• Mass Spectroscopy
• Monoclonal Antibody Technology
• Recombinant DNA Technology
• Nuclear Magnetic Resonance (NMR) Technology
• Chronic Diseases
• Autoimmune Disease
• Blood Disorders
• Growth Hormone Deficiency
• Other Applications
End Users Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other End Users
• North America
o Rest of Europe
• Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
3 Market Trend Analysis
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Biosimilars Market, By Drug Class
5.2 Recombinant Non-Glycosylated Proteins
5.2.1 Recombinant Human Growth Hormone
5.2.2 Granulocyte Colony-Stimulating Factor
5.3 Recombinant Glycosylated Proteins
5.3.2 Monoclonal Antibodies
5.4 Recombinant Peptides
5.5 Other Drug Classes
6 Global Biosimilars Market, By Manufacturing Type
6.2 In-house Manufacturing
6.3 Contract Manufacturing
7 Global Biosimilars Market, By Technology
7.2 Mass Spectroscopy
7.4 Monoclonal Antibody Technology
7.5 Recombinant DNA Technology
7.6 Nuclear Magnetic Resonance (NMR) Technology
8 Global Biosimilars Market, By Application
8.3.1 Lung Cancer
8.3.2 Brain Cancer
8.3.3 Breast Cancer
8.3.4 Cervical Cancer
8.3.5 Colorectal Cancer
22.214.171.124 Non-Hodgkin Lymphoma (NHL)
126.96.36.199 Chronic Lymphocytic Leukemia (CLL)
8.4 Chronic Diseases
8.5 Autoimmune Disease
188.8.131.52 Rheumatoid Arthritis
184.108.40.206 Psoriatic Arthritis
220.127.116.11 Juvenile Arthritis
18.104.22.168 Ankylosing Spondylitis
8.5.2 Inflammatory Bowel Disease (IBD)
22.214.171.124 Ulcerative Colitis
126.96.36.199 Crohn's Disease
8.6 Blood Disorders
8.7 Growth Hormone Deficiency
8.9 Other Applications
9 Global Biosimilars Market, By End User
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
9.5 Other End Users
10 Global Biosimilars Market, By Geography
10.2 North America
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.5 Other Key Strategies
12 Company Profiling
12.1 Coherus Biosciences Inc.
12.2 Boehringer Ingelheim International GMBH
12.3 Eli Lilly and Company
12.4 Fresenius Kabi Ag
12.5 Samsung Bioepis Co. Ltd
12.6 Amgen Inc.
12.7 LG Life Sciences (LG Chem)
12.8 Celltrion Healthcare
12.10 Dr. Reddy’s Laboratories LTD.
12.11 Viatris Inc.
12.12 Intas Pharmaceutical Ltd
12.13 Biocon Limited
12.14 Teva Pharmaceutical Industries Ltd
12.15 Pfizer Inc.
12.16 Stada Arzneimittel AG
12.17 Novartis AG
List of Tables
1 Global Biosimilars Market Outlook, By Region (2021-2030) ($MN)
2 Global Biosimilars Market Outlook, By Drug Class (2021-2030) ($MN)
3 Global Biosimilars Market Outlook, By Recombinant Non-Glycosylated Proteins (2021-2030) ($MN)
4 Global Biosimilars Market Outlook, By Recombinant Human Growth Hormone (2021-2030) ($MN)
5 Global Biosimilars Market Outlook, By Granulocyte Colony-Stimulating Factor (2021-2030) ($MN)
6 Global Biosimilars Market Outlook, By Insulin (2021-2030) ($MN)
7 Global Biosimilars Market Outlook, By Interferons (2021-2030) ($MN)
8 Global Biosimilars Market Outlook, By Recombinant Glycosylated Proteins (2021-2030) ($MN)
9 Global Biosimilars Market Outlook, By Erythropoietin (2021-2030) ($MN)
10 Global Biosimilars Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
11 Global Biosimilars Market Outlook, By Follitropin (2021-2030) ($MN)
12 Global Biosimilars Market Outlook, By Recombinant Peptides (2021-2030) ($MN)
13 Global Biosimilars Market Outlook, By Etanercept (2021-2030) ($MN)
14 Global Biosimilars Market Outlook, By Teriparatide (2021-2030) ($MN)
15 Global Biosimilars Market Outlook, By Anticoagulants (2021-2030) ($MN)
16 Global Biosimilars Market Outlook, By Other Drug Classes (2021-2030) ($MN)
17 Global Biosimilars Market Outlook, By Manufacturing Type (2021-2030) ($MN)
18 Global Biosimilars Market Outlook, By In-house Manufacturing (2021-2030) ($MN)
19 Global Biosimilars Market Outlook, By Contract Manufacturing (2021-2030) ($MN)
20 Global Biosimilars Market Outlook, By Technology (2021-2030) ($MN)
21 Global Biosimilars Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
22 Global Biosimilars Market Outlook, By Chromatography (2021-2030) ($MN)
23 Global Biosimilars Market Outlook, By Monoclonal Antibody Technology (2021-2030) ($MN)
24 Global Biosimilars Market Outlook, By Recombinant DNA Technology (2021-2030) ($MN)
25 Global Biosimilars Market Outlook, By Nuclear Magnetic Resonance (NMR) Technology (2021-2030) ($MN)
26 Global Biosimilars Market Outlook, By Electrophoresis (2021-2030) ($MN)
27 Global Biosimilars Market Outlook, By Bioassay (2021-2030) ($MN)
28 Global Biosimilars Market Outlook, By Application (2021-2030) ($MN)
29 Global Biosimilars Market Outlook, By Hematology (2021-2030) ($MN)
30 Global Biosimilars Market Outlook, By Neutropenia (2021-2030) ($MN)
31 Global Biosimilars Market Outlook, By Anemia (2021-2030) ($MN)
32 Global Biosimilars Market Outlook, By Oncology (2021-2030) ($MN)
33 Global Biosimilars Market Outlook, By Lung Cancer (2021-2030) ($MN)
34 Global Biosimilars Market Outlook, By Brain Cancer (2021-2030) ($MN)
35 Global Biosimilars Market Outlook, By Breast Cancer (2021-2030) ($MN)
36 Global Biosimilars Market Outlook, By Cervical Cancer (2021-2030) ($MN)
37 Global Biosimilars Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
38 Global Biosimilars Market Outlook, By Leukemia (2021-2030) ($MN)
39 Global Biosimilars Market Outlook, By Chronic Diseases (2021-2030) ($MN)
40 Global Biosimilars Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
41 Global Biosimilars Market Outlook, By Arthritis (2021-2030) ($MN)
42 Global Biosimilars Market Outlook, By Inflammatory Bowel Disease (IBD) (2021-2030) ($MN)
43 Global Biosimilars Market Outlook, By Psoriasis (2021-2030) ($MN)
44 Global Biosimilars Market Outlook, By Blood Disorders (2021-2030) ($MN)
45 Global Biosimilars Market Outlook, By Growth Hormone Deficiency (2021-2030) ($MN)
46 Global Biosimilars Market Outlook, By Diabetes (2021-2030) ($MN)
47 Global Biosimilars Market Outlook, By Other Applications (2021-2030) ($MN)
48 Global Biosimilars Market Outlook, By End User (2021-2030) ($MN)
49 Global Biosimilars Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
50 Global Biosimilars Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
51 Global Biosimilars Market Outlook, By Online Pharmacies (2021-2030) ($MN)
52 Global Biosimilars Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at email@example.com
Frequently Asked Questions
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: firstname.lastname@example.org or phone: +1-301-202-5929
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at email@example.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.